HMOX1 and renal cell carcinoma: Our study identified the HMOX1 pathway signature was a potential prognostic factor of progression‐free survival for TKI + IO combination therapy in the advanced RCC in different cohort, especially in first‐line management of mRCC in the Javelin 101 cohort.